Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Income from Continuing Operations for 4 consecutive years, with 12187000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 80.87% to 12187000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 105997000.0, a 29.48% increase, with the full-year FY2011 number at 116215000.0, down 14.19% from a year prior.
  • Income from Continuing Operations was 12187000.0 for Q3 2025 at Lexicon Pharmaceuticals, down from 3736000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3736000.0 in Q2 2025 to a low of 63693000.0 in Q3 2024.